New gene therapy for chronic heart failure
Official title: Novel Gene Therapy For Chronic Ischemic Heart Failure
Funded at University of Utah · NIH-11011488 · Data updated 2026-11-12
This study is testing a new gene therapy to help improve heart function in dogs with chronic heart failure, aiming to make their hearts pump better and reduce the chances of irregular heartbeats.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Utah NIH-funded |
| Lab location | 1 site (Salt Lake City, United States) |
| Project start | January 16, 2024 |
| Project end | December 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $680,971 |
| NIH project number | 5R01HL171686-02 |
| Project ID | NIH-11011488 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with chronic ischemic heart failure who have not responded well to existing therapies.
✕Less likely to help
Patients with heart failure due to non-ischemic causes or those who are not candidates for gene therapy may not benefit from this research.
What this research studies
This research focuses on developing a novel gene therapy aimed at treating chronic ischemic heart failure, a condition where the heart struggles to pump blood effectively. The approach involves using a canine model to test the effectiveness of cBIN1 gene therapy, which targets the heart muscle directly to improve calcium handling and restore heart function. By understanding how calcium microdomains are disrupted in heart failure, the researchers aim to develop a treatment that could significantly enhance heart performance and reduce the risk of arrhythmias.
Why it matters
Potential benefit: If successful, this research could lead to a groundbreaking treatment for patients suffering from chronic heart failure, potentially improving their quality of life and survival rates.
How similar studies have gone: Previous research has shown promise in using gene therapy for heart failure in small animal models, but this approach is novel in large animal models and has yet to be tested in humans.
Where this research is happening
-
University of Utah
Salt Lake City, United States Active
Researchers
- Principal investigator: Shaw, Robin M — University of Utah
- Study coordinator: Shaw, Robin M
Related research
Other NIH-funded projects on the same topics.
-
AI-supported heart failure diagnosis and management in Rwanda
Aiming to help people with suspected heart failure in Rwanda get faster, more accurate diagnoses and better care using AI-guided ultrasound and care protocols.
-
AI-assisted heart failure diagnosis in Rwanda using focused ultrasound
An NIH-funded project will test whether AI-enhanced, easy-to-use heart ultrasound can help non-experts diagnose and manage heart failure in Rwanda.
-
HF endotypes in heart failure using ethical multi-modal AI and molecular data
A patient-friendly project that uses advanced AI and multiple kinds of health data to identify distinct heart failure subtypes that could guide personalized care.
-
Triple gene therapy approach to heal the heart after a heart attack
A new therapy combines three genetic approaches delivered by a virus to help the heart heal after a heart attack.
-
Digital-first heart failure care delivery in Uganda
A targeted program in Uganda tests a digital care plan to help people with heart failure manage their symptoms at home.
-
Digital-first heart failure care delivery in Uganda
A study to test digital self-care tools to help people with heart failure in Uganda manage symptoms and stay healthier.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.